Filters
Greater severity in metabolic dysfunction-associated steatotic liver disease (MASLD) may impair cognitive function and health-related quality of life (HRQoL) in patients with overweight or obesity, suggests a study.
In patients with relapsing or progressing multiple sclerosis (MS), clinical outcomes are similar following treatment with natalizumab vs ocrelizumab, according to a retrospective study.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have the potential to reduce the frequency of migraines even in patients who do not lose weight—an effect that may be related to a reduction in intracranial pressure, according to a pilot prospective observational study.
A first-of-its-kind submillimeter magnetically actuated soft rotatable-tipped microcatheter (MSRM) developed by a cross-disciplinary research team from the Chinese University of Hong Kong (CUHK) may potentially provide faster, safer, and more precise solution for treating life-threatening blood vessel blockages in the brain.
Research on vaccine therapies for glioma has advanced markedly in recent years, with >100 glioma vaccine clinical trials currently ongoing worldwide, according to a recent update review.
People with multiple sclerosis (MS) tend to experience a lower sexual function (SF) than healthy individuals, reports a study. Age, depression, disease duration, and the Expanded Disability Status Scale (EDSS) influence SF.
Higher night‐to‐night variation in sleep duration may predispose individuals to major cardiovascular disease (CVD) events, regardless of the genetic CVD risk, according to a study.
Exposure to outdoor air pollutants such as fine particulate matter (PM2.5) and nitrogen dioxide (NO2), among others, for at least a year can put people at increased risk of dementia.
In patients with rheumatoid arthritis (RA), high disease-associated central nervous system (CNS) pain activation on functional MRI (fMRI) brain scan may help predict clinical response to TNF inhibitor treatment, as shown in a phase III study.
In the treatment of individuals with high-impact chronic pain, scalable cognitive behavioural therapy-based treatments appear to produce modest improvements in pain and related functional/quality-of-life outcomes relative to usual care, according to a study.
